614-864-4919 info@sermonixpharma.com
sermonix pharmaceutical
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Lasofoxifene
  • For Patients
    • The ELAINE Study
    • The ELAINE 2 Study
  • News & Media
    • News
    • Media
  • Medical Meetings
  • Contact
Select Page

Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer

by Sermonix Pharmaceuticals | Jul 9, 2020 | News

The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1 Mutations, is projected to begin enrollment in Q3 2020. COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...

Recent Posts

  • Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors
  • Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020
  • Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020
  • Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
  • Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada

Recent Comments

    Archives

    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org

    © 2021 Sermonix Pharmaceuticals